Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ´ç´¢º´ > ´ç´¢º´ ½ÃÀå - (2015³â±îÁöÀÇ ¿¹Ãø)
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

´ç´¢º´ ½ÃÀå - (2015³â±îÁöÀÇ ¿¹Ãø)

Diabetes Market Forecast to 2015

¸®¼­Ä¡»ç Cutting Edge Information
¹ßÇàÀÏ 2009³â 12¿ù »óǰÄÚµå 112431
ÆäÀÌÁö Á¤º¸ 324 Pages
°¡°Ý
US $ 9,995 £Ü 11,909,000 PDF by E-mail (Single User License)
US $ 31,995 £Ü 38,122,000 PDF by E-mail (Multi User License)


Cutting Edge Information ¿¡¼­ 2009³â 12¿ù ¿¡ ¹ßÇàÇÑ ¡¸´ç´¢º´ ½ÃÀå - (2015³â±îÁöÀÇ ¿¹Ãø)¡¹ º¸°í¼­´Â 324 Pages·Î ±¸¼ºµÇ¾î, US $9,995 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

´ç´¢º´ ½ÃÀå ÇöȲÀÇ »ó¼¼ÇÑ ºÐ¼®À» ÅëÇØ ÀǾàǰ ºê·£µå³ª Á¦¾àȸ»çÀÇ µ¿Çâ, ½ÃÀå Á¡À¯À², ÅõÀÚȸ¼öÀ², ºê·£µå Àü·« µîÀ» ÀüÇØµå¸³´Ï´Ù.

    Á¦1Àå ´ç´¢º´ ½ÃÀåÀÇ Áß¿ä µ¿Çâ
    • Á¶»ç ¹æ¹ý°ú Á¤ÀÇ
    Á¦2Àå ´ç´¢º´ ºê·£µå ÇÁ·ÎÆÄÀÏ
    • Àν¶¸° (Insulin)
    • ¼úÆ÷´Ò(Sulfonyl) ¿ä¼Ò
    • ¸Þ±Û¸®Æ¼³ªÀ̵å (Meglitinide)
    • Ƽ¾ÆÁ¹¸®³×µð¿Â (Thiazolidinediones)
    • DPP-4ÀúÇØÁ¦
    • GLP-1 ¾Æ³¯·Î±×
    • SGLT2 ÀúÇØÁ¦
    • ½Å±Ô ´ç´¢º´ Ä¡·áÁ¦
    • ´ç´¢º´ ÇÕº´Áõ Ä¡·á
    Á¦3Àå Áß¿ä Á¦¾àȸ»çº° °³¿ä
    • Novo Nordisk
    • Sanofi-Aventis
    • Takeda
    • Eli Lilly
    • Merck
    • GlaxoSmithKline
    • Amylin
    • Bristol-Myers Squibb
    • Roche
    • Boehringer Ingelheim
    Á¦4Àå ÇâÈÄ ´ç´¢º´ ¿¬±¸
    • ´ç´¢º´ ¿¹¹æ
    • Àν¶¸° µô¸®¹ö¸®(Insulin Delivery)ÀÇ °³¼±
    • ´ç´¢º´ ¸ÊÀÇ ÇØ¼®
    • Àν¶¸° ·çÇÁÀÇ Á¾°á
    • ´ç´¢º´ ¹Ú¸ê
    Á¦5Àå ´ç´¢º´ ½ÃÀå¿¡ ´ëÇÑ ÀÇ»çÀÇ °ßÇØ
    • Treatments and Unmet Needs
    • Unmet Needs by Region
    Á¦6Àå »ê¾÷°èÀÇ ½ÃÀå Àü¸Á
    • ½ÉÇ÷°üÁúȯ ¹ßº´¹æÁö
    • Prescibers, Emerging Treatments and Unmet Needs
    • À¯·´ ½ÃÀå
    µµÇ¥
ggy
Back to Top